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ABSTRACT 
 
 Obesity is a chronic metabolic disorder that affects all genders, ages, races, and 
socioeconomic levels, and increases the likelihood of developing other physiological or 
metabolic diseases. Considering its adipogenic inhibitory characteristics, its effect on 
sleep, and sleep’s effect on physical activity, supplementary melatonin may help combat 
this metabolic disorder. The purpose of this study was to identify trends in how 
supplementary melatonin affects sleep quality, physical activity, and body composition. 
To that end, a 14-week intervention study following an ABA single-subject design was 
conducted consisting of Ithaca College staff and faculty between ages of 40-59 years, 
with a BMI > 25 kg/m2, a normal sleep schedule (e.g., no third shift), and with stable 
exercise habits. Three participants (male n = 2, female n = 1) of age range 46-51 and a 
starting weight range of 76.3-109.3 kg completed the study. Participants underwent 12 
measurement collection sessions over the 14-week period (four during the initial baseline, 
four during the intervention period, four during the secondary baseline). During the 
intervention period, participants took a 3 mg dose of supplemental melatonin 
approximately one hour before sleep each night for eight weeks. Outcome measures 
collected included, 1) sleep quality, 2) physical activity, 3) body circumference measures 
4) waist-hip-ratio, 5) skinfolds 6) percent body fat, and 7) body mass index. Consistent 
trends across participants included a decrease in arm circumference and no change in 
sleep duration. All other outcome measures had varying trends across participants. These 
inconsistencies across participants warrant further research to account for factors that 
may have contributed to them, especially the possible impact of a dose-to-mass ratio, less 
sleep restriction, and adapting an ABAB design. 
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CHAPTER 1 
INTRODUCTION 
Obesity is a chronic metabolic disorder characterized by an increase in fat cells 
(Oliveros, Somers, Sochor, Goel, & Lopez-Jimenez, 2014). Over the past few 
decades, the prevalence of obesity in the United States has increased across all genders, 
ages, races, and socioeconomic levels (Mitchell, Catenacci, Wyatt, Hill, 2011). In 2012, 
34% of adults and 15-20% of children and adolescents were estimated to be obese 
(Akpinar, Bashan, Bozdemir, & Saatci, 2007). Obesity contributes to 5-15% of total 
annual deaths in the United States and is the fifth leading risk for global mortality, as it 
increases the risk for developing cardiovascular disease, diabetes, cancers, and 
musculoskeletal disorders (Nguyen & Lau, 2012; Oliveros et al., 2014; Zeng, Dong, Sun, 
Xie, & Cui, 2012). By decreasing weight by 5-15%, an individual can reduce their odds 
of developing these risks (Brauer et al., 2015). This is why it is important to identify 
methods to decrease the prevalence of this metabolic disorder. 
 Obesity can be diagnosed in several ways. One method is to calculate an 
individual’s body mass index (BMI), using the formula set by Adolphe Quetlet, (BMI = 
mass / height² [kg/m²]) (Gupta & Kapoor, 2014). A BMI above 25 kg/m² is considered 
overweight while a BMI above 30 kg/m² is considered obese (Akpinar et al., 2007). An 
alternative method is to measure waist circumference (WC) as well as waist-hip-ratio 
(WHR). In males, a WC ≥ 102 cm or a WHR ≥ 0.95 is considered obese, while a WC ≥ 
88 cm or a WHR ≥ 0.80 is considered obese in females (Akpinar et al., 2007). 
Additionally, an individual’s body fat percentage (BF%) can also be used to diagnose 
obesity. The American Society of Endocrinology defines obesity as an individual with a 
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BF% above 25% in males and 35% in females (Oliveros et al., 2014). Once diagnosed, 
there are various approaches to help manage obesity. 
Multiple sources recommend physical activity paired with improved diet as a 
means to lose weight (Lau et al., 2007; Wellman & Friedberg, 2002). This strategy 
decreases energy intake while increasing energy expenditure. In a recent meta-analysis, 
there was strong evidence to support that this method decreased weight and BMI by an 
average of 3.1 kg and 1.04 BMI units respectively (Brauer et al., 2015). An additional 
way to alter energy expenditure and energy intake is through sleep. A decrease in sleep 
duration increases an individual's odds of developing obesity (Rao et al., 2009). 
Decreased sleep duration increases appetite and the opportunity to intake food, while 
simultaneously decreasing thermoregulation and physical activity (Patel & Hu, 2008). 
This construct was supported when evaluating the sleep patterns and body compositions 
of 955 males, in which an inverse relationship between sleep duration and BMI was 
found (p-value, interaction = 0.035). Men who slept less than seven hours a night had a 
mean BMI that was 1.4 units higher than men who slept seven to nine hours. (Meyer, 
Wall, Larson, Laska, & Sztainer, 2012). This may be a result of a decrease in intensity 
and duration of physical activity that was found to follow a night of sleep restriction 
(Schmid et al., 2009).  
Supporting the aforementioned claims, shorter sleep duration, longer sleep onset, 
and lower sleep quality significantly raised BMI and BF% in adolescent boys (Nam, Han, 
Kim, Lee, & Seo, 2017). This is consistent across ages, as men (x̄ 	= 76.4 years) and 
women (x̄ = 83.6 years) who slept less than five hours a night had a higher BMI, BF%, 
waist circumference, and hip circumference compared to individuals who slept seven to 
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eight hours a night (Patel et al., 2008). Nevertheless, there is evidence to suggest that 
increased sleep duration is one way to lower the prevalence of obesity.  
Melatonin is a naturally occurring substance within the body; when given through 
supplementation, melatonin improves sleep behavior. A meta-analysis found melatonin 
supplementation decreased sleep onset latency and increased total sleep duration, thereby 
enhancing sleep quality (Ferracioli-Oda, Qawasmi, & Bloch, 2013). Along with 
improving sleep quality, melatonin also inhibits fat production. At the cellular level, 
melatonin prevents lipid accumulation, a process that drives adipogenesis (Sanchez-
Hidalgo et al., 2007). Furthermore, melatonin suppresses the expression of key regulators 
of adipogenesis (PPAR𝛾 and C/EBPα), by inhibiting the transcription factor C/EBP𝛽 
(Alonso-Vale, Peres, Vernochet, Farmer, & Lima, 2009). In humans, melatonin 
supplementation decreased drug-induced weight gain in adults taking medium-risk 
second-generation antipsychotics (SGAs) compared to those taking high-risk SGAs 
(Romo-Nava et al., 2014). A significant decrease in fat mass was also seen in 
postmenopausal women who underwent a one-year trial of daily melatonin 
supplementation (Amstrup et al., 2016). Given melatonin’s ability to impact sleep and its 
fat inhibitory properties, it may be an effective supplement for managing or even 
preventing obesity.  
To my knowledge, no one has investigated melatonin’s potential synergistic 
effects on sleep quality, physical activity, body circumference measurements, and body 
composition. Consequently, there is not enough evidence to warrant a large-scale 
intervention study. Instead, its potential synergy should first be explored at the individual 
level, using a single-subject design. Single-subject designs are utilized when a large 
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number of participants are unavailable or the study occurs over a period of months to 
years (Fraenkel, Wallen, & Hyun, 2015). Following an ABA design, a baseline (A) is 
identified prior to the intervention (B), which is followed by an additional baseline (A). 
With this design, the researcher can determine the effect of the independent variable on 
the dependent variable by introducing and removing the intervention (Lammers, & Badia, 
2005, Fraenkel, Wallen, & Hyun, 2015). The design has its advantages as it does not 
require random assignment and is individually focused, allowing continuous monitoring 
(Lammers, & Badia, 2005).  By implementing a single-subject design study, I will 
address questions regarding supplemental melatonin’s synergistic effects on sleep quality, 
physical activity, body circumference measurements, and body composition.  
Statement of Purpose 
The purpose of this study is to determine if a daily dose of 3 mg of melatonin over 
an eight-week period will increase sleep quality and physical activity, while decreasing 
body composition measures of males and females age 40-59 years old. 
Hypotheses 
The hypotheses for this study were: 
1. During the intervention phase while taking melatonin sleep quality will improve and 
will be reflected by a decrease in PSQI global scores. 
2. During the intervention phase while taking melatonin physical activity will increase. 
3. During the intervention phase while taking melatonin arm, waist, hip, and thigh 
circumference measures will decrease. This will also result in a decrease WHR. 
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4. During the intervention phase while taking melatonin there will be a decrease in 
chest, abdomen, and thigh skinfolds in males, as well as a decrease in triceps, 
suprailiac, and thigh skinfolds in females. This will result in a decrease in BF%. 
5. During the intervention phase while taking melatonin there will be a decrease in BMI 
that will be a product of a decrease in body mass. 
6. When entering secondary baseline sleep quality and physical activity will return to 
initial baseline measures. 
7. When entering secondary baseline circumference measures, skinfold measures, and 
weight will begin returning to initial baseline measures. 
Scope of the Problem 
Obesity is a significant issue in the United States, effecting all ages, genders, and 
races (Mitchell, Catenacci, Wyatt, Hill, 2011). It contributes to 5-15% of the country’s 
total annual deaths, and exposes individuals to the development of cardiovascular 
disease, diabetes, cancers, and musculoskeletal disorder (Nguyen & Lau, 2012; Oliveros 
et al., 2014; Zeng et al., 2012). In 2015-2016, obesity was most prevalent in males and 
females between the ages of 40-59 (Hales, Carroll, Fryar, & Ogden, 2017). In 2014, 
obesity was estimated to cost the United States $2.0 trillion annually, and has imposed 
additional costs in the form of lost workdays, lower productivity at work, permanent 
disability, and mortality (Tremmel, Gerdtham, Nilsson, & Saha, 2017). By finding 
methods to decrease the rate and development of obesity, we can reverse the 
consequences of this metabolic disorder (Brauer et al., 2015). 
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Assumptions of the Study 
For the purpose of this study, the following assumptions will be made at the start 
of each investigation: 
1. The participants are representative of a typical staff member at Ithaca College. 
2. The supplement will be taken daily an hour before sleep. 
3. Participants will maintain their usual diet throughout the study. 
4. Honest answers will be given on the sleep quality and physical activity questionnaire. 
5. All devices used to gather measurements are properly calibrated. 
Definition of Terms 
The following terms are defined for the purpose of this study: 
1. Arm Circumference - horizontal measurement at midpoint of linear measure taken 
from the acromion process of scapula to the olecranon process of the ulna, with the 
arm relaxed and hanging by the side (cm). 
2. Body Fat - the amount of adipose tissue an individual has. 
3. Body Mass Index - mass (kg) / height2 (m), description of individual’s weight relative 
to their height. 
4. External Validity - degree to which results are generalizable or applicable, to groups 
and environments outside the research setting. 
5. Hip Circumference - horizontal measurement taken at greatest protrusion of the 
gluteal muscle (cm). 
6. Internal Validity - degree to which observed differences on the dependent variable are 
directly related to the independent variable, or an uncontrolled variable. 
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7. Obesity- a chronic metabolic disorder characterized by an increase in fat cells, and 
can be diagnosed from the following characteristics: 
i. BMI > 30 kg/m2  
ii. WC ≥ 102 cm in males, ≥ 88 cm in females  
iii. WHR ≥ 0.95 in males or WHR ≥ 0.80 in females  
iv. Male: BF% > 25%, Females: BF% > 35% 
8. Single-Subject Design - an adaptation of a basic time-series design in which data is 
collected and analyzed for only one participant at a time. 
9. Sleep Quality - measure of quality and patterns of sleep in adults sepereated into: 
subjective sleep quality, sleep onset latency, sleep duration, habitual sleep efficacy, 
sleep disturbances, use of sleep medication, and daytime dysfunction over prior 
month. 
10. Thigh Circumference - horizontal measurement at midpoint of linear measure taken 
from anterior superior iliac spine of pelvis to the superior border of the patella, with 
leg in relaxed position (cm). 
11. Waist Circumference - horizontal measurement at midpoint between the lowest rib 
and the top of the iliac crest of pelvis (approximately 4 cm above the umbilicus) (cm). 
12. Waist-Hip Ratio - ratio between waist circumference and hip circumference. 
Delimitations 
The delimitations of this study include: 
1. Participants will consist of female and male staff members at Ithaca College. 
2. Sleep quality, physical activity, circumference measures, WHR, skinfolds, BF%, 
mass, and BMI will be the dependent variables assessed in this study. 
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3. Four phone calls will be made during the intervention phase to monitor adherence to 
study protocol and note any changes to lifestyle. 
4. An “ABA” single-subject design will be utilized to rule out extraneous variables. 
Limitations 
The limitations to this study include: 
1. Diet and exercise of the participants will not be controlled. 
2. Individuals will not be taking melatonin supplementation in presence of researcher. 
3. A single-subject design makes it difficult to extrapolate results to other populations. 
4. The use of an ABA single-subject design does not allow for intra-participant 
reliability.  
5. Data collector bias is also acknowledged, for the researcher is also collecting the data. 
6. Instrumental decay may occur, as the data collector must perform many 
measurements for each participant multiple times throughout the duration of the 
study. 
7. Use of Lange calipers to assess %BF instead of	gold-standard (underwater weighing).
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CHAPTER 2 
REVIEW OF LITERATURE 
 Obesity not only exposes individuals to developing additional diseases and 
disorders, but also carries a large financial burden on the United States (Nguyen & Lau, 
2012; Oliveros et al., 2014; Tremmel, Gerdtham, Nilsson, & Saha, 2017; Zeng et al., 
2012). This is why it is necessary to uncover methods of treating this metabolic disorder. 
This review outlines the diagnosis, associated risk factors, and management 
recommendations of obesity. Additionally, a major section covers the effect of sleep on 
obesity, and how sleep may be altered via melatonin supplementation. The review 
finishes by examining the additional effects that supplemental melatonin may have on an 
individual’s body composition as well as the best study design to explore such a novel 
idea.	
Obesity 
Epidemiology 
 The obesity epidemic has continued to rise since the 1980’s (Akpinar et al., 
(2007). Over the past few decades in the United States, the prevalence of obesity has 
increased across all genders, ages, races, and socioeconomic levels (Mitchell, Catenacci, 
Wyatt, Hill, 2011). In 2012, it was estimated that 34% of the adult population and 15-
20% of children were obese (Akpinar et al., 2007). The U.S. Department of Health and 
Human Services reported the highest prevalence of obesity in males and females between 
ages of 40-59 years old (Hales et al., 2017). This metabolic disorder causes missed 
workdays, lower productivity at work, permanent disability, and increased mortality, 
costing the United States an estimated $2 trillion in the year 2017 (Tremmel et al., 2017). 
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This increases the need to prevent and treat obesity, as it is a physical and economic 
burden. 
Definitions of Obesity 
 Obesity can be diagnosed by calculating an individual’s body mass index (BMI); 
this relates the mass and height of an individual using the formula of (BMI = mass / 
height² [kg/m²]). A BMI > 25 kg/m² is considered overweight, while a BMI > 30 kg/m² 
classifies an individual as obese (Akpinar et al., 2007). An alternative method is to 
measure an individual’s waist circumference (WC) as well as calculate their waist-hip-
ratio (WHR). In males, a WC ≥ 102 cm or a WHR ≥ 0.95 is considered obese, while a 
WC ≥ 88 cm or a WHR ≥ 0.80 is considered obese in females (Akpinar et al., 2007). 
Additionally, when evaluating body composition the American Society of Endocrinology 
defines obesity as an individual with a BF% above 25% in males and 35% in females 
(Oliveros et al., 2014). This is calculated by running an individual’s sum of skinfolds and 
age through a regression equation that predicts body density and BF%. The location of 
each skinfold site was predetermined based off of the regression equation used (Miller, 
2012). No matter the method, diagnosis of obesity is important as it gives rise to multiple 
health risks. 
Risk Factors 
A high BMI increases the risk of morbidity and premature mortality from 
cardiovascular disease, diabetes, cancers, and musculoskeletal disorders (Nguyen, & Lau, 
2012). Similarly WC is positively correlated to mortality, as a 10% increase in WC 
corresponds with a 1.48 times higher mortality rate across both sexes (Bigaard et al., 
2005). Furthermore, a higher WHR is associated with a greater risk of developing chronic 
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diseases such as hypertension, cardiovascular disease, Type II diabetes, stroke, and 
mortality (Akpinar et al., 2007). Lastly, high BF% is a better predictor of cardiovascular 
risk compared to BMI, as individuals with a normal BMI who had a higher BF% 
exhibited a similar cardiovascular risk profile of those with a high BMI and BF% (Zeng 
et al., 2012). By finding methods to decrease the rate and development of obesity, we can 
reduce the risk of developing these secondary diseases (Brauer et al., 2015). 
Management 
Multiple sources have recommended the use of physical activity paired with an 
improved diet as the first line of treatment (Lau et al., 2007; Wellman & Friedberg, 
2002). This strategy decreases energy intake while increasing energy expenditure (Brauer 
et al., 2015). Recommended changes include increasing the consumption of fruit, 
vegetables, wholes grains, and low fat products. This coincides with a decrease in 
sedentary behaviors and increase in physical activity. The simultaneous change in diet 
and activity was found to decrease mass by an average of 3.1 kg, lower BMI by 1.04 
units, and decrease WC by 3.05 cm (Brauer et al., 2015). Despite the positive results, 
recent studies may have identified an additional intervention to consider.  
Effects of Sleep on Body Mass Index 
An alternative method to impact body composition may be through improved 
sleep quality. Decreases in sleep time increase an individual's odds to develop obesity 
(Rao et al., 2009). Upon evaluation of sleep patterns and body compositions of 955 
males, an inverse relationship between sleep duration and BMI (p-value, interaction = 
0.035) was seen (Meyer et al., 2012). Men who slept for less than seven hours a night had 
a mean BMI 1.4 units higher than men who slept seven-to-nine hours. An increase by one 
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hour of sleep lowered BMI by 0.38 units and reduced the odds of becoming obese by 
0.14 (Meyer et al., 2012). This same result was replicated, but with a 10% reduction in 
the odds of becoming obese with an additional hour of sleep (Lawman, D. Fryar, Gu, & 
Ogden, 2016). 
These changes are linked to the fact that sleep restriction alters appetite regulating 
hormones, thereby increasing appetite (Patel & Hu, 2008; Wu, Zhai, & Zhang, 2015). 
Additionally, a lack of sleep provides greater opportunity for food intake. Collectively 
these changes increase an individual’s energy intake (Patel & Hu, 2008; Wu et al., 2015). 
Aside from increased energy intake, lack of sleep decreases energy expenditure. Likely 
because of increased fatigue, as intensity and duration of physical activity decreased 
following a night of sleep restriction (Schmid et al., 2009). Additionally, less sleep causes 
a drop in core body temperature resulting in a decrease in thermoregulation activity (Patel 
& Hu, 2008). Together, an increase in appetite, greater opportunity for food intake, an 
increase in fatigue, and decrease in thermoregulation it is no wonder that sleep duration 
has an inverse relationship with BMI. 
As for how the relation between sleep duration and BMI translates to other 
variables, a shorter sleep duration, longer sleep latency, and lower sleep quality 
significantly raised BMI and BF% in adolescent boys (Nam et al., 2017). This is 
consistent across ages, as men (x̄		= 76.4 years) and women (x̄		= 83.6 years) who slept 
less than five hours had a higher BMI 2.48 kg/m2 (95% CI: [2.02, 2.93]) and BMI 1.75 
kg/m2 (95% CI: [2.02, 2.93]) respectively (p < 0.0001) for both (Patel et al., 2008). 
Additionally circumference measures were higher, 6.7 cm (95% CI: [5.4, 8.0]) in men 
and 5.4 cm (95% CI: [1.0, 9.9]) higher in females, at the waist. At the hip, compared to 
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those with seven to eight hours of sleep, men and women who slept less than five  hours 
had a 4.7 cm (95% CI: [3.7, 5.7]) and 5.0 cm (95% CI: [1.0, 8.9]) higher circumference 
respectively (Patel et al., 2008). Considering the relationships between sleep duration and 
the aforementioned body composition measures, increasing sleep quality could be a 
helpful method in treating obesity. This could be accomplished via melatonin 
supplementation. 
Introduction of Melatonin 
Endogenous Melatonin 
Melatonin is an endogenous hormone that is primarily produced and secreted by 
the pineal gland in almost all of animals (Amstrup et al., 2016; Kim et al., 2005). The 
production and release of melatonin is controlled by the suprachiasmatic nucleus (SCN) 
of the hypothalamus, which is responsible for modulating an individual's circadian 
rhythm (Seabra, Bignotto, Pinto, & Tufik, 2000). This is also known as the awake and 
sleep cycle and it is synchronized with daylight (Amstrup et al., 2016). When it is light 
out, melatonin production is inhibited, whereas when it is dark, the SCN stimulates 𝛽 and 
α-noradrenic receptors of pinealocytes, which secrete melatonin (Seabra et al., 2000). 
Serum concentration levels peak between 2:00-4:00 am and gradually decline as light 
comes along (Amstrup, Sikjaer, Heickendorff, Mosekilde, & Rejnmark, 2015; Seabra et 
al., 2000). Aside from the pineal gland, cells found in bone marrow can also produce 
melatonin (Sanchez-Hidalgo et al., 2007). When released, melatonin enters the 
bloodstream and is distributed throughout the body where it interacts with bodily organs 
and the nervous system (Seabra et al., 2000). 
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Exogenous Melatonin 
Aside from endogenous production, melatonin can be acquired through 
exogenous sources. It is available over-the-counter and widely utilized throughout the 
United States. Studies show that exogenous melatonin does not induce dependence 
potential or tolerance build up, and has few side effects (Ferracioli-Oda et al., 2014). A 
meta-analysis assessed the efficacy and safety of exogenous melatonin, and concluded 
that 1-5 mg of melatonin is a safe short-term supplement over a three-month period. The 
most common adverse effects were headaches, dizziness, nausea, and drowsiness. When 
compared to the placebo group, there was no significant difference in adverse symptoms 
experienced. This is consistent with another study in which 5 mg of melatonin was paired 
with second-generation antipsychotic (SGA) medication in 44 patients over an eight-
week period. Throughout the trial, melatonin did not affect symptom severity; this 
suggests it is a safe over-the-counter supplement to use (Romo-Nava et al., 2014). For the 
past couple decades, melatonin has primarily been used as a treatment for sleep disorders 
(Ferracioli-Oda et al., 2014). Recent findings, however, show that melatonin is more than 
just a sleep aid, as it also positively influences metabolic function, adiposity and, 
therefore, body mass (Prunet-Marcassus et al., 2003). 
Melatonin’s Effect on Sleep 
 Two meta-analyses, Brzezinski et al. (2005) and Ferracioli-Oda et al. (2013), 
evaluated the role that melatonin plays in an individual's sleep quality. The first, 
Ferracioli-Oda et al. (2013), evaluated melatonin’s effectiveness in influencing sleep in 
individuals diagnosed with a sleeping disorder. Melatonin decreased the onset of sleep by 
7.06 minutes, increased total sleep duration by 8.25 minutes and, as a result, improved 
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sleep quality (Ferracioli-Oda et al., 2013). The second meta-analysis, Brzezinski et al. 
(2005), evaluated individuals without a diagnosed sleep disorder; here melatonin 
decreased sleep onset latency by 3.9 minutes, increased sleep duration by 13.7 minutes, 
and improved quality of sleep by 3.1% (Brzezinski et al., 2005). Considering the inverse 
relationship between sleep and body composition, these data suggest that supplementary 
melatonin may successfully control obesity. 
Melatonin’s Effect on Adipogenic Inhibition 
Cellular Evidence 
Aside from impacting sleep, evidence suggests that melatonin supplementation 
can regulate obesity through other mechanisms. Sanchez-Hidalgo et al. (2007) evaluated 
the effect of melatonin on the cell lineage of bone marrow mesenchymal stem cells 
(MSC). The MSC have two cell lineages; they undergo osteogenic differentiation to form 
osteocytes, or in the presence of fatty acids, they adapt the characteristics of adipocytes, 
therefore promoting adipogenesis. In this study, rat osteoblastic cells were incubated with 
oleic-acid, inducing triglyceride accumulation that caused the MSC to follow an 
adipogenic cell lineage. When added, melatonin inhibited any farther lipid accumulation, 
halting the process of adipocyte proliferation (Sanchez-Hidalgo et al., 2007). Further 
evaluating the mechanism, melatonin receptor antagonists (luzindole and forskolin) were 
administered to the incubated cells. This reversed the inhibitory mechanism of melatonin 
allowing triglyceride to accumulate. This indicated that the inhibition of triglyceride 
accumulation is a melatonin-mediated mechanism and melatonin directly influences the 
production of adipocytes (Sanchez-Hidalgo et al. 2007).  
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This latter finding by Sanchez-Hidalgo et al. (2007) may be a result of 
melatonin’s ability to inhibit critical transcription factors in adipogenesis. The 
proliferation of preadipocytes is driven by hypertrophy or hyperplasia of fat cells. An 
increase in fat cells directs CCAAT/enhancer binding protein beta and delta (C/EBPβ and 
CEBPδ) transcription factors to initiate adipogenesis. Once C/EBPβ or C/EBPδ are 
present they generate the expression of peroxisome proliferator-activated receptor gamma 
(PPARγ) or CAAT/ enhancer binding protein alpha (C/EBP α). These key regulators 
activate the final stage of adipocyte generation (Alonso-Vale et al., 2009). When present, 
melatonin decreased the presence of PPARγ, C/EBPα and transcription factor C/EBPβ 
(Alonso-Vale et al., 2009). Collectively, the two aforementioned studies demonstrate 
melatonin’s inhibitory effect on adipogenesis.  
Systemic Evidence of Melatonin 
The aforementioned results have been supported in both animal and human 
studies. In one study, melatonin altered body mass, adiposity, energy intake, and energy 
expenditure of Sprague rats (Prunet-Marcassus et al., 2003). Two groups of Sprague rats 
were fed a high fat or high carbohydrate diet over a three-week period with some rats in 
each group receiving 30 mg/kg of melatonin. Melatonin decreased body mass 5-6% in 
rats on the high fat diet, with no difference seen in the high carbohydrate rats after three 
weeks. The rats then underwent a pinealectomy to prevent endogenous melatonin 
secretion. This resulted in an increase in body mass that was reversed when given 
supplemental melatonin. They also found that the decrease in body mass was only 
significant in the rats that had previous energy imbalances, compared to those who started 
with normal body masses (Prunet-Marcassus et al., 2003). This suggests that melatonin 
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may have more of a positive influence on body composition in those with an energy 
imbalance such as being overweight or obese. 
 As for its influence on the body composition in humans, melatonin had a 
significant effect on decreasing weight gain in postmenopausal women (Walecka-Kapica 
et al., 2015). This is from its ability to decrease estradiol levels, which is significant 
because estradiol levels are inversely proportional to urinary 6-sulphatoxymelatonin 
(aMT6s) levels, and aMT6s is negatively correlated with BMI. Consequently melatonin 
could decrease the chance of developing obesity in postmenopausal women by 
decreasing estradiol levels, thereby increasing aMT6s concentration, resulting in a lower 
BMI (Walecka-Kapica et al., 2015). 
 In a second study, the metabolic effect of a 5 mg daily dose of melatonin over an 
eight-week period taken in combination with SGAs was evaluated. These SGAs are 
associated with drug-induced weight gain in patients with bipolar disorder and 
schizophrenia. Researchers tested if melatonin could prevent this weight gain, and found 
it decreased weight gain in bipolar individuals receiving medium-risk SGAs, whereas it 
increased weight gain in schizophrenic individuals taking high-risk SGAs (Romo-Nava, 
et al., 2014). Unfortunately, the use of psychotropic drugs paired with each individual’s 
metabolic profile in conjunction with melatonin is a major limitation to the study, making 
it hard to accept the results (Romo-Nava, et al., 2014). 
 Lastly, body composition was evaluated in osteopenic postmenopausal women 
who participated in a one-year trial of daily melatonin supplementation. Participants were 
split into three groups with one group taking 1 mg of melatonin daily, the second 3 mg, 
and the final receiving a placebo. A significant decrease in BF% was identified in the 
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melatonin groups compared to the control with a decrease of 6.9% (p = 0.02), without a 
significant change in body mass or BMI (Amstrup, et al., 2016). Collectively, these 
studies suggest that melatonin may function as a means to alter body composition. To 
determine this I have developed a 14-week single-subject design study to evaluate this 
theory. 
Single-Subject Design 
 Single-subject designs are commonly used to collect and analyze data of one 
participant over a period of time when an intervention is administered (Lammers & 
Badia, 2005). These designs are often utilized when a large number of participants are 
unavailable and often occur over months to years (Fraenkel et al., 2015). Furthermore, a 
single-subject design is often utilized to evaluate the effect of an intervention on an 
individual in the early stages of a treatments development (Lammers & Badia, 2005). 
They can follow various models such as AB, ABA, or ABAB designs, in which a 
baseline (A) is identified prior to the intervention (B) being administered (Lammers, & 
Badia, 2005). Following an ABA model the researcher is able to control for threats to 
internal validity by determining the effect of the independent variable on the dependent 
variable (Fraenkel, Wallen, & Hyun, 2015). This is done by collecting data before, 
during, and after the intervention is administered. Not requiring random assignment or a 
control group is a major advantage to the single-subject design as participants act as their 
own control. When performing the statistical analysis, single-subject designs rely on 
descriptive statistics (Lammers, & Badia, 2005). This is often illustrated using a line 
graph to present the effects of the intervention or treatment (Fraenkel, Wallen, & Hyun, 
2015). An important aspect in the statistical analysis is establishing a proper baseline. A 
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well-established baseline will consist of four experimental sessions with which the target 
measurement/s does not vary by more then five percent (Lammers, & Badia, 2005). From 
here the researcher can further strengthen their results by creating a 95% confidence 
interval around the initial baseline. Another way to the strengthen results is by replicating 
the data. Intra-participant reliability occurs when the same results are seen in the same 
participant, while inter-participants reliability is when results are seen in other 
participants undergoing the same intervention (Fraenkel, Wallen, & Hyun, 2015). From 
the information above, an ABA single-subject design is the best fit for the study that will 
be performed. 
The Gap 
 Supplemental melatonin does show evidence of improving body composition. 
What remains unclear is what is the cause of these changes. Improvements may stem 
from supplemental melatonin’s adipogenesis inhibitory properties or also it’s ability to 
influence sleep. As previously mentioned, supplemental melatonin does increase sleep 
duration, which has an inverse relationship with a variety of body composition measures. 
Additionally an increase in sleep duration results in less fatigue leading to an increase in 
physical activity, which increases energy expenditure thereby promoting weight loss. 
With so many variables it is difficult to determine which has the greatest influence on 
body composition. To help determine this, a 14-week single-subject design study was 
developed in which the effects of melatonin supplementation on three individual’s sleep 
quality, physical activity, and body composition was evaluated. 
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CHAPTER 3 
METHODS 
Participants 
Three individuals participated in the study. All were Ithaca College staff and/or 
faculty members between ages of 40-59 years, with a BMI > 25 kg/m2, a normal sleep 
schedule (e.g., no third shift), and maintained their typical exercise habits (Table 1). 
Further exclusion criteria were set in accordance with the supplement’s manufacturer 
guidelines (Appendix A). Additionally, a board certified physician served as the safety 
officer on the protocol and approved all participants for inclusion in the study. 
Study Procedure 
The current study, which was approved by the Ithaca College Institutional Review 
Board, followed an ABA single-subject design, in which an initial baseline (A) was 
identified over the course of two weeks, followed by an eight-week intervention period 
(B). Participants then underwent a two-week washout period prior to collecting a 
secondary baseline (A) over an additional two-weeks (Appendix B). Following 
recruitment, a one-on-one meeting was scheduled with each participant in room 309 in 
the Center for Health and Sciences at Ithaca College. Here the researcher discussed the 
study and handed out the informed consent form (Appendix C). Participants were given 
the opportunity to have their questions or concerns addressed. Consent was obtained once 
all questions were answered and the participant accepted and understood the procedures, 
risks, and ability to withdraw from the study at any point. 
On each visit, participants reported to the Body Composition Lab Room 303D in 
the Center for Health Sciences at Ithaca College. On the first day a simple demographic  
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Table 1 
 
Summary of Participant Demographics 
 
 Sex Age Height Mass 
Participant 1 Male 47 170.8 cm 109.3 kg 
Participant 2 Male 46 171.3 cm 76.3 kg 
Participant 3 Female 51 167.1 cm 83.5 kg 
Note: Summary of participant sex, age, height, and mass. 
form was filled out (Appendix D), followed by the measurement collection session.  
Body Mass Index (BMI) 
Participants were asked to remove their shoes and height was measured to the 
nearest 0.1 cm using a Tanita stadiometer (Arlington Heights, IL). Height was measured 
on the first visit and held constant for the remainder of the study. Mass was measured 
using a Detecto® eye-level weight beam scale (Detecto, Webb City MO) and measured 
to the nearest 0.1 kg. From these measurements BMI was calculated using (BMI = body 
mass / height² (kg/m²)) (Gupta, & Kapoor, 2014). 
Pittsburgh Sleep Quality Index (PSQI)  
Participants then filled out the Pittsburgh Sleep Quality Index (PSQI) (Appendix 
E). This is a self-reported questionnaire that contains nineteen individual items. These 
items are combined into seven component scores (sleep quality, sleep latency, sleep 
duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime 
dysfunction) that are weighted on a scale of 0-3 (Buysse, Reynolds III, Monk, Berman, & 
Kupfer, 1989). Component scores are added up to create one global score (0-21); with a 
high global score signifying poor sleep quality. The seven components of the PSQI have 
been found to have a high reliability coefficient (Cronbach α = 0.83). This self-reported 
questionnaire has a sensitivity of 89.6% and specificity of 86.5% in classifying good 
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sleepers vs. those with diagnosed sleep disorders or depression (Backhaus, Junghanns, 
Broocks, Riemann, & Hohagen, 2002). The PSQI has an intersession correlation of 0.85 
(p < 0.001) with no significant difference between scores during separate sessions 
(Buysee et al., 1989). 
International Physical Activity Questionnaire – Short Form (IPAQ-SF)  
Following the PSQI, participants completed the International Physical Activity 
Questionnaire – Short Form (IPAQ-SF) (Appendix F). This is a self-reported 
questionnaire that consists of seven items, all of which are open-ended questions, 
regarding the type and duration of physical activity the participant partook in as well as 
time spent sitting over the previous seven days. Compared to the long form version of the 
IPAQ-SF was found to produce a Spearman’s ρ cluster ranging from (p = 0.65-0.81). It 
also carries a median criterion validity (p = 0.3), categorizing it as an acceptable 
measurement tool in monitoring physical activity among 18-65 year old adults (Craig et 
al., 2003). 
Circumference Measures 
Following the questionnaires, circumference measures were measured using a 
cloth measuring tape following the procedures set by Reiman and Manske (2009). Arm 
circumference was taken at the halfway point between the acromion process and 
olecranon process, with the arm relaxed and hanging by the side. Waist circumference 
was measured at the midpoint between the lowest rib and the top of the iliac crest 
(approximately 4 cm above the umbilicus). Hip circumference was taken at the level of 
greatest protrusion of the gluteal muscle. Thigh circumference was taken half way 
between the anterior superior iliac spine and the proximal border of the patella with the 
		
23	
leg relaxed. All circumference measurements were taken on the right side of the body 
when applicable and measured to the nearest 0.1 cm. Duplicate measures were taken at 
each site. If the measurements differed by more than 0.6 cm then a third measurement 
was taken (Miller, 2012). The individual’s WHR was calculated from the average waist 
and hip circumference measures using (WHR = waist circumference / hip circumference) 
(Reiman, & Manske, 2009). 
Skinfold Measurements 
 Each skinfold measure was taken on the right side of the body using a Lange 
skinfold caliper. In males, skinfolds were taken at the chest (diagonal fold taken half the 
distance between the axillary line and the nipple), abdomen (horizontal fold, 2 cm to the 
right of the umbilicus), and thigh (vertical fold on the anterior midline of thigh, midway 
between the proximal border of patella and inguinal crease). In females, skinfolds were 
taken at the triceps (vertical fold on the posterior midline of upper arm, midway between 
the acromion process and olecranon process), suprailiac (diagonal fold in line with the 
natural angle of the iliac crest taken in the anterior axillary line) and thigh (vertical fold 
on the anterior midline of thigh, midway between the proximal border of patella and 
inguinal crease). Each measurement was taken twice, unless there was greater than a 3-
millimeter difference, in which a third skinfold was taken. The average of these 
measurements determined the individual’s body density (BD). BD was then inputted into 
the Brozek equation, which calculated %BF. 
Males: 
 BD = 1.10938 – 0.0008267 (sum of 3 sites) + 0.0000016 (sum of 3 sites)2 – 
 0.0002572 (age) 
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Females: 
 BD = 1.099421 – 0.0009929 (sum of 3 sites) + 0.0000023 (sum of 3 sites)2 – 
 0.0001392 (age) 
%BF = [4.570 / BD (kg/m3) – 4.142] x 100 (Miller, 2012) 
The Brozek equation was chosen because it is strongly correlated to dual X-ray 
absorptiometry device (r = .91, p < 0.001) in its accuracy in calculating BF% in older 
adults (Guerra, Amaral, Marques, Mota, & Restivo, 2010). Body density was calculated 
using the equations in the NSCA’s Guide to Tests and Assessment (Miller, 2012). 
Equations and skinfold sites used have been validated with a correlation of 0.98 between 
the sum of three and seven skinfold sites in males and an intercorrelation of (r < 0.966) in 
females when comparing body density calculations using three, four, or seven site 
skinfolds (Jackson & Pollock, 1978; Jackson, Pollock, & Ward, 1980). 
Each measurement collection session followed the aforementioned procedure and 
was completed four times over a two-week period to establish a baseline (A) (Fraenkel, 
Wallen, & Hyun, 2015) (Appendix G). This was followed by the intervention phase (B), 
where participants were handed a manufacturer sealed, 120-count, 3 mg dose of 
melatonin (Nature Made®, Northridge CA). They were instructed to take one tablet of 
melatonin once a day, an hour before sleep, for an eight-week period. Throughout the 
intervention phase, participants had their mass, circumference measures, skinfolds, sleep 
quality, and physical activity assessed every two-weeks. A phone call was administered 
every other week when participants did not come in for measurements to keep up to date 
with the adherence to the study protocol (Appendix H). At the end of the intervention 
phase the researcher collected the melatonin tablets to prevent the participant from taking 
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the supplement during the secondary baseline. The remaining tablets were counted to 
ensure compliance to the protocol. 
Participants then entered a two-week wash out period, during which they did not 
come in for measurement collections or take melatonin. After the two-week wash out 
period, the secondary baseline phase began. Following the same procedure as the initial 
baseline, four measurement collection sessions occurred over a two-week period. At the 
conclusion of the secondary baseline the participants were given the remaining melatonin 
supplements and released from the study. 
Reliability and Responsiveness of the Outcome Measures 
In order to establish his own reliability and responsiveness estimates on these 
outcome measures, the researcher initially piloted his ability to capture the outcome 
measures on 10 individuals who consented to have these measures assessed in two testing 
sessions over the course of one week.  In Table 2, the results of the intersession reliability 
calculated using intraclass correlation coefficient analysis (ICC) are presented along with 
the corresponding standard error of the measure (SEM) and minimum detectable change 
(MDC = SEM × 1.96) as measures of responsiveness (Appendix I). 
Statistical Analysis 
 With the single-subject design, trends were identified though visual inspection of 
the graphed outcome measures. To allow for appropriate cutoffs for potentially 
meaningful changes, a 95% confidence minimal detectable change (MDC) was calculated 
around the mean of the initial baseline for each participant. Any data points that fell 
outside of these confidence intervals were considered to be a potentially meaningful 
change. 
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CHAPTER 4 
RESULTS 
 No adverse events were reported during the study. Participant 1 reported dizziness 
upon waking the morning following the first dose of melatonin, which subsided after the 
first few days. Participant 2 reported increased dreaming, which subsided after the initial 
two weeks of melatonin supplementation. Participant 3 experienced feeling excessively 
warm upon waking at night. This unanticipated event was reported to the safety officer, 
who approved the participant’s continuation in the study after concluding that this effect 
was considered to be safe. The unanticipated effect continued throughout the duration of 
the intervention period. Participant 3 also reported waking up with extreme hunger late 
into the intervention phase, which she associated to an increased work. 
 Over the eight-week intervention phase, participant 1 missed taking three 
melatonin capsules (95% compliance), participant 2 missed three capsules (95% 
compliance), and participant 3 missed one capsule over the eight-weeks (98% 
compliance). This resulted in a 96% compliance rate across all participants. 
 
 
 
 
 
 
		
27	
Participant 1 
 In participant 1, the outcome measures that appeared most sensitive to change 
were waist circumference, arm circumference, hip circumference, and PSQI global 
scores. Each variable demonstrated a decreasing trend supporting my hypotheses. 
Alternatively, the outcome measures of thigh skinfold and body fat percentage showed a 
trend toward increasing contrary to what was hypothesized. Further results are illustrated 
in the following figures (Figures 1-13). Additionally, throughout the observation periods, 
participant 1 demonstrated a downward trend in his mass, approximately1.68 kg over the 
study period (Figure 14). 
 
 
Figure 1. Participant 1 Arm 
Circumference 
Intervention phase: Arm circumference 
decreased with two points almost 
exceeding the MDC. 
Secondary baseline: Arm circumference 
continued to decrease and three points 
exceeded MDC. 
 
Figure 2. Participant 1 Waist 
Circumference 
Intervention phase: Waist circumference 
decreased with three points exceeding 
the MDC. 
Secondary baseline: Waist 
circumference continued to decrease 
with three points exceeding the MDC. 
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Figure 3. Participant 1 Hip 
Circumference 
Intervention phase: Hip circumference 
decreased with one point exceeding the 
MDC. 
Secondary baseline: Hip circumference 
no longer continued to decrease and no 
points exceeded the MDC. 
 
 
Figure 5. Participant 1 Thigh 
Circumference 
Intervention phase: No meaningful 
changes noted. 
Secondary baseline: Thigh 
circumference began to decrease, but 
failed to exceed the MDC. 
 
Figure 4. Participant 1 Waist-Hip-Ratio 
Intervention phase: No meaningful 
changes noted. 
Secondary baseline: Waist-Hip-Ratio 
began to decrease, but did not exceed the 
MDC. 
 
 
 
 
Figure 6. Participant 1 Chest Skinfold 
Intervention phase: No meaningful 
changes were noted despite one point 
exceeding the MDC. 
Secondary baseline: Chest skinfolds 
begin to increase and one point exceeded 
the MDC. 
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Figure 7. Participant 1 Abdominal 
Skinfold 
Intervention phase: No meaningful 
changes noted. 
Secondary baseline: No meaningful 
changes noted. 
 
 
 
Figure 9. Participant 1 Percent Body 
Fat 
Intervention phase: Percent body fat 
increased with one point exceeding the 
MDC. 
Secondary baseline: Percent body fat 
remained elevated with two points 
exceeding the MDC. 
 
 
Figure 8. Participant 1 Thigh Skinfold 
Intervention phase: Thigh skinfolds 
begin to increase and four points 
exceeded the MDC. 
Secondary baseline: Thigh skinfolds no 
longer continued to increase, but all four 
points exceeded the MDC. 
 
 
Figure 10. Participant 1 Body Mass 
Index 
Intervention phase: No meaningful 
changes noted. 
Secondary baseline: Body mass index 
began to decrease but failed to exceed 
the MDC. 
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Figure 11. Participant 1 Pittsburgh 
Sleep Quality Index 
Intervention phase: PSQI global score 
initially decreased with the first two 
points exceeding the MDC. Scores then 
increased for the remaining duration. 
Secondary baseline: PSQI global scores 
return to initial baseline values without 
exceeding the MDC. 
 
 
Figure 13. Participant 1 Weekly Activity 
vs. Pittsburgh Sleep Quality Index 
Intervention phase: Physical activity 
increased without any relation to PSQI 
global scores. 
Secondary baseline: Physical activity 
decreased without any relation to PSQI 
global scores. 
 
Figure 12. Participant 1 Sleep Duration 
vs. Pittsburgh Sleep Quality Index 
Intervention phase: Sleep duration did 
not show meaningful changes despite the 
improvement in sleep quality.     
Secondary baseline: Sleep duration did 
not show meaningful changes despite the 
decrease in sleep quality. 
 
 
 
Figure 14. Participant 1 Body Mass 
Intervention phase: No meaningful 
change was seen in body mass. 
Secondary baseline: Body mass began to 
decrease. 
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Participant 2 
 Across the duration of the study, the outcome measures that appeared most 
sensitive to change were abdominal circumference, thigh skinfold, percent body fat, and 
PSQI global scores. These variables demonstrated a downward trend, supporting my 
hypotheses. Further results are illustrated in the following figures (Figures 15-27). 
Throughout the observation periods, participant 2 demonstrated a downward trend in his 
mass, losing approximately 2.68 kg over the course of the study period (Figure 28). 
 
 
Figure 15. Participant 2 Arm 
Circumference 
Intervention phase: No meaningful 
changes noted, but decreasing trend in 
arm circumference was noted. 
Secondary baseline: Trend of decreasing 
arm circumference continued and 
reached or exceeded the MDC. 
 
Figure 16. Participant 2 Waist 
Circumference 
Intervention phase: Waist circumference 
begins to decrease with one point 
exceeding the MDC. 
Secondary baseline: The first two 
measurements exceed the MDC, but then 
begin to increase. 
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Figure 17. Participant 2 Hip 
Circumference 
Intervention phase: No meaningful 
change with all points failing to exceed 
the MDC. 
Secondary baseline: No meaningful 
change although points near exceeding 
the MDC. 
 
 
Figure 19. Participant 2 Thigh 
Circumference 
Intervention phase: Thigh circumference 
decreased with one point almost 
exceeding the MDC. 
Secondary baseline: Thigh 
circumference continues to drop and two 
points exceed the MDC. 
 
Figure 18. Participant 2 Waist-Hip-
Ratio 
Intervention phase: No meaningful 
change with all points failing to exceed 
the MDC. 
Secondary baseline: Waist-hip-ratio 
begins to increase after the first 
measurement exceeded the MDC. 
 
 
Figure 20. Participant 2 Chest Skinfold 
Intervention phase: Chest skinfolds 
decrease although no points exceed the 
MDC. 
Secondary baseline: No meaningful 
change with all points failing to exceed 
the MDC. 
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Figure 21. Participant 2 Abdominal 
Skinfold 
Intervention phase: Abdominal skinfolds 
decrease with one point exceeding the 
MDC. 
Secondary baseline: Skinfolds continue 
to decrease with two points exceeding 
the MDC. 
 
 
Figure 23. Participant 2 Percent Body 
Fat 
Intervention phase: Percent body fat 
decreases with two points exceeding the 
MDC.  
Secondary baseline: Measures continue 
to decrease with all four exceeding the 
MDC. 
 
Figure 22. Participant 2 Thigh Skinfold 
Intervention phase: Thigh skinfolds 
decrease with one point exceeding the 
MDC. 
Secondary baseline: Skinfolds continue 
to decrease with all four exceeding the 
MDC. 
 
 
 
Figure 24. Participant 2 Body Mass 
Index 
Intervention phase: Body mass index 
decreased all points failed to exceed the 
MDC. 
Secondary baseline: Body mass index 
continued to decrease, again with all 
points failing to exceed the MDC. 
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Figure 25. Participant 2 Pittsburgh 
Sleep Quality Index 
Intervention phase: PSQI global score 
initially decreased with the first three 
points exceeding the MDC, with the 
final score beginning to increase. 
Secondary baseline: PSQI global scores 
return to initial baseline values without 
exceeding the MDC. 
 
 
Figure 27. Participant 2 Weekly Activity 
vs. Pittsburgh Sleep Quality Index 
Intervention phase: Weekly activity did 
not show meaningful changes despite the 
improvement in sleep quality. 
Secondary baseline: Weekly activity did 
not show meaningful changes despite the 
decrease in sleep quality. 
 
Figure 26. Participant 2 Sleep Duration 
vs. Pittsburgh Sleep Quality Index 
Intervention phase: Sleep duration did 
not show meaningful changes despite the 
improvement in sleep quality. 
Secondary baseline: Sleep duration did 
not show meaningful changes despite the 
decrease in sleep quality. 
 
 
	
Figure 28.Participant 2 Body Mass 
Intervention phase: Body mass began to 
decrease. 
Secondary baseline: Body mass 
continued to decrease. 
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Participant 3 
 Across the duration of the study, the outcome measures that appeared most 
sensitive to change were arm circumference, thigh circumference, and thigh skinfold. 
These variables demonstrated a downward trend, supporting my hypotheses. Further 
results are illustrated in the following figures (Figures 29-41). Throughout the 
observation periods, participant 3 demonstrated a downward trend in her mass, losing 
approximately 2.72 kg over the course of the study period (Figure 42). 
 
	
Figure 29. Participant 3 Arm 
Circumference 
Intervention phase: Arm circumference 
decreased with two points almost 
exceeding the MDC. 
Secondary baseline: Arm circumference 
continued to decrease with all four 
points exceeding the MDC. 
 
Figure 30. Participant 3 Waist 
Circumference 
Intervention phase: No meaningful 
changes noted, despite one point 
exceeding the MDC. 
Secondary baseline: Waist 
circumference continued to decrease and 
all four points exceeded the MDC. 
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Figure 31. Participant 3 Hip 
Circumference 
Intervention phase: Hip circumference 
decreased with one point exceeding the 
MDC. 
Secondary baseline: Hip circumference 
continued to decrease and one point 
exceeded the MDC. 
 
	
Figure 33. Participant 3 Thigh 
Circumference 
Intervention phase: Thigh circumference 
decreased with one point exceeding the 
MDC. 
Secondary baseline: Thigh 
circumference continued to decrease 
with two points exceeding the MDC. 
 
Figure 32. Participant 3 Waist-Hip-
Ratio 
Intervention phase: No meaningful 
changes noted, with all points failing to 
exceed the MDC. 
Secondary baseline: Waist-Hip-Ratio 
began to decrease with one point 
exceeding the MDC. 
 
 
Figure 34. Participant 3 Triceps 
Skinfold 
Intervention phase: Triceps skinfolds 
initially decreased with the one point 
exceeding the MDC. 
Secondary baseline: Skinfolds continued 
to decrease with two points exceeding 
the MDC, before increasing in the end. 
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Figure 35. Participant 3 Suprailiac 
Skinfold 
Intervention phase: No meaningful 
changes noted. 
Secondary baseline: No meaningful 
changes noted. 
 
 
 
	
Figure 37. Participant 3 Percent Body 
Fat 
Intervention phase: Percent body fat 
initially decreased with the one point 
exceeding the MDC. 
Secondary baseline: Percent body fat 
continued remained lowered with one 
point exceeding the MDC. 
 
	
Figure 36. Participant 3 Thigh Skinfold 
Intervention phase: Thigh skinfolds 
initially decreased with the two points 
exceeding the MDC, and then began to 
increase. 
Secondary baseline: Skinfolds 
demonstrated no meaningful changes, 
despite one point exceeding the MDC. 
 
 
Figure 38. Participant 3 Body Mass 
Index 
Intervention phase: Body mass index 
decreased all points failed to exceed the 
MDC. 
Secondary baseline: Body mass index 
continued to decrease, again with all 
points failing to exceed the MDC. 
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Figure 39. Participant 3 Pittsburgh 
Sleep Quality Index 
Intervention phase: No meaningful 
changes noted. 
Secondary baseline: PSQI global score 
initially decreased with the first three 
points exceeding the MDC, with the 
final score beginning to increase. 
 
	
Figure 41. Participant 3 Weekly Activity 
vs. Pittsburgh Sleep Quality Index 
Intervention phase: Weekly activity did 
not show meaningful changes despite the 
improvement in sleep quality. 
Secondary baseline: Weekly activity did 
not show meaningful changes despite the 
decrease in sleep quality. 
 
Figure 40. Participant 3 Sleep Duration 
vs. Pittsburgh Sleep Quality Index 
Intervention phase: Sleep duration did 
not show meaningful changes despite the 
improvement in sleep quality. 
Secondary baseline: Sleep duration did 
not show meaningful changes despite the 
decrease in sleep quality. 
 
 
Figure 42. Participant 3 Body Mass 
Intervention phase: Body mass began to 
decrease. 
Secondary baseline: Body mass 
continued to decrease. 
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CHAPTER 5 
DISCUSSION 
 The purpose of this study was to determine if a daily 3 mg dose of melatonin over 
an eight-week period would increase sleep quality and physical activity, while decreasing 
body composition measures of males and females age 40-59 years old. To my knowledge 
no study has collectively evaluated supplemental melatonin and its influence on these 
outcome measures. This exploratory study compared trends to current literature, and 
addressed concerns regarding safety, feasibility, residual effects, and compliance, prior to 
performing a larger group study. 
 Of the three participants enrolled in this study, participant 1 did not demonstrate 
many changes in body composition despite having a high compliance rate. Participant 2 
demonstrated substantial changes in body composition while having the same compliance 
rate as participant 1. Participant 3, who had the highest compliance rate of all, 
demonstrated substantial changes on many of the measures of body composition.  
 During the intervention period all participants had a trend in decreasing arm 
circumference. A downward trend was seen in hip circumference in participants 1 and 3, 
WC in participants in 1 and 2, and thigh circumference in participants 2 and 3. No 
participants showed a significant change in WHR. Participants 2 and 3 had a downward 
trend in thigh skinfolds and BF, while participant 1 showed an increasing trend in the 
same measures. Of the males, participant 2 had a trend of decreasing chest and abdominal 
skinfolds. The one female participant had a trend towards decreasing triceps skinfolds, 
and showed no change in suprailiac skinfolds. As for body mass, participants 2 and 3 
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showed a trend towards decreasing mass during the intervention phase, which was paired 
with a decrease in BMI.  
 Sleep quality improved for participants 1 and 2 during the intervention phase, and 
returned to initial baseline measures during the secondary baseline period. Participant 3 
was the only one to experience a decrease in sleep quality, which returned to initial 
baseline measures after finishing the intervention period. None of the participants 
experienced a fluctuation in sleep duration while taking supplemental melatonin. As for 
physical activity, only participant 1 demonstrated a trend toward increasing through the 
study. 
Dosage Response 
 In the current study, participants with a lower BMI had better results in regard to 
changes in their body composition compared to the participant with a higher BMI. 
Participant 2 had the lowest starting BMI and showed trends towards decreasing 
measurements in all body composition outcomes except WHR. Comparatively, 
Participant 1, who had the highest starting BMI, showed the most varying results; some 
body composition outcomes decreased while others increased. This may be due to a 
varying dose response in participants, considering each participant took a 3 mg of 
supplemental melatonin without regard to body mass. It is possible that the varying 
responses were due to the dose-to-mass ratio, considering the substantial difference in 
mass between the two male participants. This brings to attention that larger doses of 
melatonin may be needed to elicit the same response in those with a higher BMI. The 
possibility of a dose response has been evaluated in females, and was found that females 
who took 3 mg of supplemental melatonin compared to 1 mg did not show greater 
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improvements in body composition (Amstrup et al., 2016). Although this does not align 
with my hypothesis of a dose-to-mass ratio, with such sparse evidence in humans 
examining a dosage/mass ratio in participants still warrants further exploration. 
Sex Response 
An additional area of future consideration should evaluate if an individual’s 
biological sex influences their response to melatonin. At this point the literature contains 
evidence mainly in female participants, with limited results in males. Participant 3 being 
the only female participant did show trends towards decreasing measures in a majority of 
body composition outcomes, most specifically in body mass and BMI. This was 
consistent with what was expected as females with higher serum melatonin levels were 
less likely to gain weight and have a lower BMI (Walecka-Kapica et al., 2015). As for the 
two male participants, each of them had different body composition outcomes. 
Participant 2, who had a lower BMI compared to Participant 3 demonstrated trends 
consistent with the literature. This data suggests that sex may not impact response to 
melatonin, and supports the idea that there may be a related response. Further, sex 
comparisons are difficult, as only one study has investigated the impact of melatonin on 
males, but the concurrent use of antipsychotic medication severely limits the results 
(Romo-Nava et al., 2014). As with dose-to-mass ratio, sex differences warrants additional 
research. 
Daily Schedule Influence on Sleep 
Melatonin improved sleep quality in the two male participants while in the 
intervention phase. Participant 3 experienced a decrease in sleep quality during the 
intervention phase. Whether participants experienced improved or decreased sleep 
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quality, there was no fluctuation in sleep duration. This is surprising, as multiple sources 
have concluded that supplemental melatonin improves sleep quality as well as sleep 
duration (Brzezinski et al., 2005; Ferracioli-Oda et al., 2013). These inconsistencies in 
the fact that sleep duration was expected to increase, but evidently did not, may be 
explained by the participants’ daily routines. Despite taking a known supplement to 
increase sleep (Brzezinski et al., 2005; Ferracioli-Oda et al., 2013), participants were still 
required to wake up at the same time in order to go to work. This means that even if 
melatonin did have a positive effect on sleep duration the extraneous variable of having 
to wake up for work may have altered the results. With this in mind, it would be worth 
considering a participant’s daily morning routine when recruiting for future studies. 
Ideally participants would be able to wake up on their own to eliminate this extra 
variable. 
Changes in Mass and BMI 
 Through the duration of the study, participants 2 and 3 showed a trend towards 
weight loss and a decreasing BMI. These trends occurred despite no changes in the 
participants sleep duration or physical activity. This comes as a surprise considering BMI 
and sleep duration have an inverse relationship, meaning less sleep is associated with a 
higher BMI (Meyer et al., 2012). Because sleep duration and physical activity did not 
change, it can be inferred that there was also no change in energy availability or 
expenditure to account for this weight loss (Brauer et al., 2015). Instead, perhaps the 
weight loss in participants 2 and 3 is attributed to melatonin’s adipogenic inhibitory 
factors (Alonso-Vale et al., 2009). Interestingly, the participants’ weight continued to 
decrease following the intervention phase in the secondary baseline phase. Considering 
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supplemental melatonin has a half-life of approximately two hours, it is unlikely that 
residual melatonin in the body system is the cause of this result (Gooneratne et al., 2012). 
This indicates there may be an additional variable accounting for this continued weight 
loss. A more concise or controlled evaluation of diet, exercise, and sleep is important to 
consider in future studies. 
Safety 
 According to the manufacturer label, common side effects of supplemental 
melatonin include headaches, dizziness, nausea, and drowsiness. Only one participant 
experienced any of the aforementioned side effects. Participant 1 reported dizziness upon 
waking the morning following the first dose of melatonin. This side effect did not 
continue the duration of the intervention period and the participant continued to be 
compliant with the intervention. As for participant 2 and 3 minor novel side effects were 
experienced, as they are not stated on the label or reported in the literature.  Participant 2 
reported increased dreaming when first taking supplemental melatonin, which subsided 
after the initial two weeks. Participant 3 was the only one to experience a side effect 
throughout the intervention period. This participant woke up multiple times in the night 
feeling excessively warm, but reported no concern about this effect and continued the 
intervention. This was reported to the safety advisor, who cleared the participant. 
Participant 3 also reported waking up with extreme hunger in the later stages of the 
intervention phase. She associated it with excessive stress stemming from an increased 
workload (Appendix K-L). All of the reported side effects were considered minor and did 
not raise any major health concerns. The low rate of side effects supports the idea that 
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melatonin is a safe short-term supplement in doses of 1-5 mg when taken during a three-
month period (Buscemi et al., 2005). 
Compliance 
 The intervention phase required the participant to take their dose of melatonin an 
hour before going to sleep. This meant that the supplement was not taken in the presence 
of the researcher, which could threaten the rate of compliance. To ensure compliance, the 
researcher checked in every other week with participants to ask if they were maintaining 
the study protocol, timing, and dosage of melatonin. Additionally, the researcher counted 
the remaining melatonin capsules at the end of the intervention period. Over the eight-
week intervention phase participants 1 and 2 missed taking three capsules, resulting in a 
95% compliance rate. Participant 3 had the highest compliance rate at 98%, only missing 
one capsule over the eight-weeks. Missed dosage may be due to forgetfulness or the fact 
that consumers hold lower compliance intentions when considering over-the-counter 
medications, in general, compared to prescription drugs (Bower, Grau, & Taylor, 2013). 
Despite this fact, the current study showed almost perfect compliance, which helps 
address concern about participant compliance in future studies.  
Residual Effect 
 It is important to consider the possible residual effect of taking supplemental 
melatonin. Considering supplemental melatonin functions as a sleep aid, a concern is 
residual fatigue the following morning (Brzezinski et al., 2005; Ferracioli-Oda et al., 
2013). This was not the case for any of the participants that completed this study. No 
participants reported feeling excessively tired in the morning or throughout the day when 
taking the supplement. A lack of residual fatigue is supported by the IPAQ-SF of 
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participants 2 and 3 who did not experience a change in physical activity, and participant 
1 who showed a trend towards increasing activity. This lack of residual fatigue may be 
due to melatonin’s short half-life. Even when taken in higher dose (2 mg-10 mg), 
melatonin has an elimination half-life of approximately two hours, with a return towards 
baseline in about 10 hours (Gooneratne et al., 2012). Although this time frame exceeded 
the participants sleep duration, the current study only utilized a 3mg dose. This means the 
participant’s melatonin levels may not have been elevated for the full 10-hour period, as 
reported. Either way, from evidence collected in the three participants, it seems unlikely 
that residual fatigue should be a concern for future studies. 
Feasibility 
 All three participants that underwent the initial baseline completed all 
measurement collection sessions. Over the course of the study, participants came in for 
12 measurement collection sessions that took approximately 20 minutes each visit. 
Participants also received a five-minute phone call on four occasions during the 
intervention period. The only additional requirement was to take the daily melatonin 
supplement an hour before bed. Altogether, over 14-weeks, the study required 
approximately five hours of the participant’s time. The small time requirement over the 
course of the study paired with the 100% completion rate helps ensure the feasibility of 
my methodological approach. The completion rate is much higher than what was 
expected, considering the 27% attrition rate associated with longitudinal studies 
(Goodman & Blum, 1996). The positive results in safety, compliance, residual effects, 
and feasibility help address the concerns of performing a similar study with more 
participants. 
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Limitations 
 Despite the single-subject designs strength in a patient orientated approach, it 
brings upon various threats to internal and external validity. Starting with internal validity 
the first threat was the expected speed of change of outcome measures. The literature 
lacks evidence on how long supplemental melatonin must be taken until improvements in 
body composition are seen. This study utilized an eight-week period, which is 
significantly shorter than a similar study that followed a yearlong period of supplemental 
melatonin (Amstrup et al., 2016). An increase in the duration of the intervention period 
would ensure that the intervention administered would have the needed time to take 
effect. A second limitation involved the type of single-subject design that was utilized. 
With an ABA design the researcher identified if body composition measures returned to 
initial baseline values upon removal of the intervention. Unfortunately this did not allow 
for intra-participant replication. Introducing an ABAB design would add a second 
intervention phase. If the second intervention period yielded the same results as the first, 
the replicated results would hold more value, thereby increasing internal validity. 
 As for threats to external validity, it is hard to advocate the use of a treatment 
based off of the results of a single-subject design. Working with such few participants 
paired with the various threats to internal validity make it difficult to extrapolate results 
out to a larger population. Once again replication of results is key to increasing the 
generalizability of the research results. This could be done in two ways 1) by running the 
participants who are similar to the participants from this study through the same study or 
2) introducing an ABAB design. Through replication of results the degree to which 
changes in body composition are directly related to supplemental melatonin would be 
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strengthened, resulting in an increase in internal validity. Once these threats to internal 
validity are accounted for the researcher can generalize the results out to populations 
outside of the study, thereby improving the external validity.  
Reflection 
 When considering future avenues of exploration, applying a dose-to-mass ratio 
response should be considered first. This could be accomplished by recruiting additional 
male and female participants with varying BMIs. By doing so, the researcher can identify 
if individuals with higher BMIs show the same trends as those with lower BMIs. This 
would allow for inter-participant replication, which would strengthen any results seen. It 
is important that the dosage of melatonin remains the same to ensure that BMI is the only 
altered variable. Incorporating this method to future studies would bring light of the 
possible dose-to-mass response. 
 Another consideration would be to recruit participants who do not have sleep 
restraint. In the current study, no increase in sleep duration was seen, which may have 
been due to the fact that participants were still required to wake up each morning at a set 
time to go to work. Considering that sleep quality and duration were an outcome 
measure, it would be best to eliminate any variable that could influence either. In future 
studies, participants with a more flexible sleep schedule should be considered. By doing 
so, the researcher would eliminate a further extraneous variable, further improving the 
internal validity. 
 Additionally, altering the study design and adapting an ABAB design would also 
be beneficial. This added intervention phase would provide two benefits. First, it could 
provide a means of replication between each intervention phase. If body composition 
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measures improve in both the first and second intervention phase then this would 
strengthen the results of the study. Alternatively, a placebo could be introduced during 
the second intervention phase. This would provide details of whether melatonin was 
directly influencing the outcome measures or whether other extraneous variables are in 
play. No matter the choice, adding an additional intervention period could strengthen the 
internal validity of the study.  
 It is also worth considering extending the duration of the study, which could be 
accomplished by increasing each phase of the study design. By increasing the baseline 
periods a more accurate depiction of each participant’s normal values could be 
completed. This extended baseline period would also allow the opportunity to administer 
additional measurement collection sessions, further increasing the strength of each 
baseline. Additionally, increasing the intervention phase would allow more time for the 
supplement to have an effect on the physiologic measures of body composition. 
Especially considering these measures are not expected to change quickly, extending the 
intervention phase would further clarify if supplemental melatonin does have an effect on 
physiologic measures of body composition. 
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CHAPTER 6 
SUMMARY, CONCLUSIONS, RECOMMENDATIONS 
Summary 
 The purpose of this study was to determine if a daily 3 mg dose of melatonin 
would increase sleep quality and physical activity, while decreasing body composition 
measures of males and females age 40-59 years old. To answer this question three 
participants underwent a 14-week single-subject design study in which their sleep quality, 
physical activity, and body composition were assessed periodically. This exploratory 
study compared trends to the current literature, and addressed concerns regarding safety, 
feasibility, residual effects, and compliance. 
Conclusions 
 When evaluating body composition, supplemental melatonin demonstrated 
consistent trends in decreasing the arm circumference in all participants. As for its 
influence on sleep, the only consistent trend was that no participants experienced any 
change in sleep duration. Lastly, looking at physical activity, only one participant 
demonstrated an increase in weekly activity. As for the remaining outcome, participant’s 
results were inconsistent across outcome measures when compared to each other. These 
inconsistencies across many of the outcome measures made it difficult to form conclusive 
results on the effect of supplemental melatonin on body composition.  This study did 
however bring to attention areas for future consideration that could further strengthen the 
internal validity of the study such as 1) looking into a dose-to-mass ratio response, 2) 
considering the sleep restraints on participants, and 3) introduce an ABAB single-subject 
design. Additionally, this study showed positive results in regards to safety, compliance, 
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and feasibility. In the end, this single-subject design study accomplished what it was 
intended to do, which was to provide trends to compare to the current literature and 
identified future areas of exploration. 
Recommendations 
	 At this time, using supplemental melatonin as a method to improve body 
composition measures should not be advised. There are still many future areas to explore 
before any conclusive results can be generalized and recommended to the public. 
Examining a dose-to-mass ratio, recruiting a population with less sleep restriction, 
following an ABAB design, or extending the study duration are all areas that need to be 
considered. Performing additional research accounting for the aforementioned 
recommendations would greatly increase the internal validity of the study, which is a 
must, prior to making recommendations for the use of supplementary melatonin as a 
means of improving body composition. 
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APPENDIX A 
Exclusion Criteria Form 
Participant Number:___________________        
       (Investigators Use Only) 
 
Have you been diagnosed with: 
        Hypertension       Diabetes     Asthma    Seizures  
       
  Endocrine Autoimmune Disorder     Bleeding Disorder        
 
Are you currently pregnant, looking to become pregnant, or nursing?   
   Yes     No 
  
Are you currently taking any of the following? 
   Melatonin Supplements           Anti-Depressants           Antianxiety Medication          
   Diabetic Medication                Narcotics                        Asthma Medication                
   Blood Pressure Medication 
 
Other Criteria 
  I verify I am between 40-59 years old 
 
  I verify that I do not currently work overnight shifts (3rd shift) 
 
  I verify that I am not planning on starting an exercise program in the next 14 week
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APPENDIX B 
Outline of Study Design 
Figure 43 Outline of Study Design 
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Informed Consent Form 
Daily melatonin supplementation influence on body composition and sleep quality 
over an eight-week experimental trial 
1. Purpose of the Study 
The purpose of this study is to determine if a daily dose of 3 mg of melatonin over an eight-week 
period will increase sleep quality and decrease the body fat percentage of male and females age 40-59 
years old. 
 
2. Benefits of the Study 
You will receive a report of your current body composition at no cost. This will include measures such 
as height, weight, BMI, percent body fat, and circumference measurements. You may experience 
improved sleep and a decrease in body fat, which can decrease the chance of developing chronic 
diseases associated with high fat mass. These results are not guaranteed and are the reason why this 
study is being performed. At the end of the study you will be given the remaining amount of melatonin 
tablets to do what you wish with them. Completion of this study will help me write my thesis and 
complete my Master’s in Exercise and Sport Sciences. Your participation will also help scientists 
evaluate other possible benefits and uses of melatonin supplementation other than controlling sleep. 
 
3. What You Will Be Asked to Do 
In order to participate you must meet the following criteria: 
• Be an Ithaca College staff member between the ages 40-59 years old 
• You should not participate if you are currently taking melatonin supplements, anti-
depressants, antianxiety medications, diabetic medication, narcotics, blood pressure 
medication, or asthma medication 
• You should not participate if you are pregnant, looking to become pregnant, nursing 
• You should not participate if you are diagnosed with hypertension, diabetes, depressive 
disorder, bleeding disorder, seizure disorder, or an endocrine autoimmune disorder 
• You should not participate if you plan are starting an exercise routine over the course of the 
study 
• You should not participate if you work over night shifts (3rd shifts) 
• You will be unable to participate if you have a body mas index below 25 kg/m2 
 
       If you meet the criteria then you will be asked to: 
• Take a 3 mg melatonin supplementation once a day for an eight-week period 
• Come in every two weeks in a T-shirt or tank top and shorts to get your weight, percent body fat, 
and circumference measurements taken 
o Height will be measured with your shoes off and your back against the wall 
o Weight will be measured using a weight beam scale  
o Circumference measurements will be taken at you waist and hip using a measuring tape 
o Percent body fat will be calculated by taking skinfold measurements taken at the: 
§ Males: chest, abdomen, and front of thigh 
§ Females: back of arm, along the top of the hip bone, and the front of the thigh 
o This entire process should take less than 15 minutes 
• Every two weeks you will also be asked to fill out a sleep quality and physical activity 
questionnaire  
o This will take an additional 10 minutes for those sessions 
• In total measurement sessions should take anywhere from 20-25 minutes  
Initials:_____________ 
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• Every two weeks you will receive a 10 minutes phone call to assess your progress in the study 
• The entire study will take approximately 5 hours of your time over a 14-week period 
 
4. Risks 
The possible risks for being in this study are the side effects that may occur from the melatonin 
supplementation. The most common side effects are headaches, dizziness, nausea, and drowsiness, if 
these symptoms occur contact the lead researcher. It has been demonstrated that in doses of 1-5 mg, 
melatonin is a safe short-term supplement when taken during a three-month period. The dosing 
procedure for the study follows the label of the company the made the melatonin. This means the risk 
of injury is not higher for this study than it would be if you decided to take this supplement yourself. 
The researcher will also call you every two-two weeks to check in on you, in order 
to guarantee your safety in participation. In the circumstance that you experience severe dizziness, 
difficulty breathing, cardiovascular problems, or any other medical emergency, seek medical attention 
immediately. Call 911. 
 
5. Compensation for Injury 
If you suffer an injury that requires any treatment or hospitalization as a direct result of this study, the 
cost for such care will be charged to you.  If you have insurance, you may bill your insurance 
company.  You will be responsible to pay all costs not covered by your insurance.  Ithaca College will 
not pay for any care, lost wages, or provide other financial compensation. 
 
6. If You Would Like More Information about the Study 
If you have questions regarding this study, you may contact Nathan Oakes, at (207) 316-0031, or 
noakes@ithaca.edu 
 
7. Withdraw from the Study 
You are free to stop participating in the study at any time. Just tell the researcher that you would like to 
stop participating and you will be released from the study. 
 
8. How the Data will be Maintained in Confidence 
Your data will be kept confidential on a password-protected computer. Only the researchers will have 
access to the data. The data on the computer as well as any forms will be coded by participant number. 
I will only present data by participant number. Only the researcher will have access to the names 
associated with the code, and the code will be kept separate from the data files in a secure location. All 
data collected will be kept for a minimum of 3 years and electrical data will be stored on a password-
protected computer in a faculty member’s office. 
 
I have read the above and I understand its contents.  I agree to participate in the study.  I acknowledge that I 
am 18 years of age or older.  
 
_____________________________________________________ 
Print or Type Name 
_____________________________________________________ ____________________ 
Signature Date
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Simple Demographic Form 
Participant Number_____________________  Date_______________ 
 
The information below will allow us to provide an accurate description of the sample. 
For the following items, please select the one response that is most descriptive of you. 
 
Age:_______________ 
 
Gender: 
    Female      Male 
 
Race / Ethnicity: 
     Asian or Pacific Islander       Asian Indian 
    African American (non-Hispanic)      Caucasian / White 
    Native American        Latino / Hispanic 
    Other / More then one race (specify)_________________________
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Pittsburg Sleep Quality Assessment (PSQI) 
Participant Number_____________________  Date_______________ 
 
What is the PSQI, and what is it measuring? 
The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure 
the quality and patterns of sleep in adults. It differentiates “poor” from “good” sleep 
quality by measuring seven areas (components): subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping 
medications, and daytime dysfunction over the last month. 
INSTRUCTIONS: 
The following questions relate to your usual sleep habits during the past month only. 
Your answers should indicate the most accurate reply for the majority of days and 
nights in the past month. Please answer all questions. 
During the past month, 
1. When have you usually gone to bed?             ____________ 
2. How long (in minutes) has it taken you to fall asleep each night? ____________ 
3. What time have you usually gotten up in the morning?           ____________ 
4. A. How many hours of actual sleep did you get at night?           ____________ 
B.  How many hours were you in bed?             ____________ 
5. During the past month, how often have you had trouble sleeping 
because you 
Not during 
the past 
month (0) 
Less than 
once a 
week (1) 
Once or 
twice a 
week (2) 
Three or 
more times 
a week (3) 
A.  Cannot get to sleep within 30 minutes     
B.  Wake up in the middle of the night or early morning     
C.  Have to get up to use the bathroom     
D.  Cannot breathe comfortably     
E.  Cough or snore loudly     
F.  Feel too cold     
G. Feel too hot     
H. Have bad dreams     
I.  Have pain     
J. Other reason (s), please describe, including how often you have had 
trouble sleeping because of this reason (s): 
    
6. During the past month, how often have you taken medicine 
(prescribed or “over the counter”) to help you sleep? 
    
7. During the past month, how often have you had trouble staying awake 
while driving, eating meals, or engaging in social activity? 
    
8. During the past month, how much of a problem has it been for you to 
keep up enthusiasm to get things done? 
    
9.  During the past month, how would you rate your sleep quality 
overall? 
Very good 
(0) 
Fairly 
good (1) 
Fairly bad 
(2) 
Very bad (3) 
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Scoring 
 
Component 1  #9                C1_____ 
 
Component 2  #2 Score (< 15 min (0), 16-30 min (1), 31-60 min (2), > 60 (3)) 
 + #5a Score (sum is equal 0 = 0, 1-2 = 1, 3-4 = 2, 5-6 = 3) 
  C2_____ 
 
Component 3  #4 Score (> 7 (0), 6-7 (1), 5-6 (2), < 5 (30)           C3_____ 
 
Component 4  (total # of hours asleep) / (total # of hours in bed) x 100  
 > 85% = 0, 75-84% = 1, 65-74% = 2, < 65% = 3   
                 C4_____ 
 
Component 5  # sum of scores 5b-5j (0 = 0, 1-9 = 1, 10-18 = 2, 19-27 = 3) 
         C5_____ 
 
Component 6  #6                C6_____ 
 
Component 7  #7 Score + #8 Score (0 = 0, 1-2 = 1, 3-4 = 2, 5-6 = 3)       C7_____ 
 
 
Add the seven component scores together____________ Global PSQI________
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International Physical Activity Questionnaire – Short Form 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires. Long (5 activity domains asked independently) and short (4 generic 
items) versions for use by either telephone or self-administered methods are 
available. The purpose of the questionnaires is to provide common instruments that 
can be used to obtain internationally comparable data on health–related physical 
activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in 
Geneva in 1998 and was followed by extensive reliability and validity testing 
undertaken across 12 countries (14 sites) during 2000.  The final results suggest 
that these measures have acceptable measurement properties for use in many 
settings and in different languages, and are suitable for national population-based 
prevalence studies of participation in physical activity. 
 
Using IPAQ 
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It 
is recommended that no changes be made to the order or wording of the questions 
as this will affect the psychometric properties of the instruments. 
 
Translation from English and Cultural Adaptation 
Translation from English is supported to facilitate worldwide use of IPAQ. 
Information on the availability of IPAQ in different languages can be obtained at 
www.ipaq.ki.se. If a new translation is undertaken we highly recommend using the 
prescribed back translation methods available on the IPAQ website. If possible 
please consider making your translated version of IPAQ available to others by 
contributing it to the IPAQ website. Further details on translation and cultural 
adaptation can be downloaded from the website. 
 
Further Developments of IPAQ 
International collaboration on IPAQ is on-going and an International Physical 
Activity Prevalence Study is in progress. For further information see the IPAQ 
website. 
 
More Information 
More detailed information on the IPAQ process and the research methods used in 
the development of IPAQ instruments is available at www.ipaq.ki.se and Booth, 
M.L. (2000). Assessment of Physical Activity: An International Perspective. 
Research Quarterly for Exercise and Sport, 71 (2): s114-20. Other scientific 
publications and presentations on the use of IPAQ are summarized on the website. 
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We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives. The questions will ask you about the time you spent being 
physically active in the last 7 days. Please answer each question even if you do not 
consider yourself to be an active person. Please think about the activities you do at 
work, as part of your house and yard work, to get from place to place, and in your spare 
time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days. Vigorous 
physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal. Think only about those physical activities that you 
did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous 
physical activities like heavy lifting, digging, aerobics, or fast 
bicycling? 
 
   days per week 
 
No vigorous physical activities Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical activities on 
one of those days? 
 
   hours per day 
   minutes per day 
 
Don’t know/Not sure 
 
Think about all the moderate activities that you did in the last 7 days. Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal. Think only about those physical activities that you did 
for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles 
tennis? Do not include walking. 
 
   days per week 
 
No moderate physical activities Skip to question 5 
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4. How much time did you usually spend doing moderate physical activities on 
one of those days? 
 
   hours per day 
   minutes per day 
 
Don’t know/Not sure 
 
 
Think about the time you spent walking in the last 7 days. This includes at work and at 
home, walking to travel from place to place, and any other walking that you have done 
solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time? 
 
   days per week 
 
No walking Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
   hours per day 
   minutes per day 
 
Don’t know/Not sure 
 
The last question is about the time you spent sitting on weekdays during the last 7 
days. Include time spent at work, at home, while doing course work and during leisure 
time. This may include time spent sitting at a desk, visiting friends, reading, or sitting or 
lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a weekday? 
 
   hours per day 
   minutes per day 
 
Don’t know/Not sure
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Measurement Collection Sheet 
BMI: 
Height:__________ (m)              Weight:__________ (kg)       BMI:__________ (kg/m2) 
Circumference Measures: 
* Take third measure if first two differ by 0.6 cm 
 Measurement 1 Measurement 2 Measurement 3        
(If needed) 
Average 
Arm Circ. cm cm cm cm 
Waist Circ. cm cm cm cm 
Hip Circ. cm cm cm cm 
Thigh Circ. cm cm cm cm 
 
WHR:__________ (Average WC / Average HC) 
 
Skinfold Measures:                                                                                               
* Take third measure if first two differ by 3.0 mm 
 
Male 
 Measurement 1 Measurement 2 Measurement 3        
(If needed) 
Average 
Chest mm mm mm mm 
Abdominal mm mm mm mm 
Thigh mm mm mm mm 
Female 
 Measurement 1 Measurement 2 Measurement 3        
(If needed) 
Average 
Triceps mm mm mm mm 
Suprailiac mm mm mm mm 
Thigh mm mm mm mm 
	 	
69	
APPENDIX G - Continued 
Body Density: 
Male 
BD = 1.10938 – 0.0008267 (sum of 3 sites) + 0.0000016 (sum of 3 sites)2 – 0.0002572 
(age) 
BD = 1.10938 – 0.0008267 (___________) + 0.0000016 (___________)2 – 0.0002572 
(_______) 
BD = 1.10938 – ____________________ + ____________________ – 
___________________ 
BD = ___________________ 
Female 
BD = 1.099421 – 0.0009929 (sum of 3 sites) + 0.0000023 (sum of 3 sites)2 – 0.0001392 
(age) 
BD = 1.099421 – 0.0009929 (__________) + 0.0000023 (__________)2 – 0.0001392 
(_________) 
BD = 1.099421 – ____________________ + ____________________ – 
___________________ 
BD = ___________________ 
Body Fat: 
%BF = [4.570 / BD (kg/m3) – 4.142] 
%BF = [4.570 / _____________ (kg/m3) – 4.142] 
%BF = ___________________
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Bi-weekly Check-in Script 
Hello, 
 
This is Nathan Oakes calling. I am checking in for an update on you progress with the 
study. I have a few questions for you to answer. 
 
Have you been taking your melatonin supplementation daily, an hour before bed? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___________________________________________________ 
 
Have you experienced any side effects?  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___________________________________________________ 
 
Have you made any major changes to your life style (diet / exercise / hobby)? 
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___________________________________________________ 
 
When would you be available to come in for your measurements next week? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___________________________________________________ 
 
Do you have any questions for me? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___________________________________________________ 
 
Thank you for your participation in the study. If you need to reach me you can give me a 
call at (207) 316-0031. In the circumstance that symptoms do arise, contact your primary 
care provider.
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Intraclass Correlation Coefficients  
Table 2. 
Summary of ICC, SEM, and MDC Values of Pilot Study  
 
 ICC 
95% CI 
Value SEM 95% MDC Lower Bound Upper Bound 
BMI 0.947 0.595 0.993 P = 0.004 0.48 1.33  
AC 0.976 0.901 0.994 P < 0.001 0.54 cm 1.50 cm 
WC 0.990 0.961 0.997 P < 0.001 1.11 cm 3.08 cm 
HC 0.979 0.920 0.995 P < 0.001 0.81 cm 2.24 cm 
TC 0.960 0.836 0.900 P < 0.001 0.79 cm 2.18 cm 
WHR 0.976 0.907 0.994 P < 0.001 0.01 0.03 
CS 0.919 0.682 0.980 P = 0.001 1.66 mm 4.60 mm 
AS 0.961 0.845 0.990 P < 0.001 2.13 mm 5.92 mm 
TriS 0.988 0.920 0.998 P < 0.001 0.98 mm 2.72 mm 
SS 0.941 0.693 0.991 P < 0.001 3.29 mm 9.13 mm 
TS 0.996 0.986 0.999 P < 0.001 0.78 mm 2.15 mm 
%BF 0.989 0.959 0.997 P < 0.001 0.70 % 1.94 % 
Note: Values were calculated from pilot study (n=10)  
ICC = Intraclass Correlation Coefficient, 95% CI = 95% Confidence Interval, SEM = 
Standard Error of Measure, 95% MDC = 95% Minimal Detectable Change, BMI = Body 
Mass Index, AC = Arm Circumference, WC = Waist Circumference, HC = Hip 
Circumference, TC = Thigh Circumference, WHR = Waist-Hip-Ratio, CS = Chest 
Skinfold, AS = Abdominal Skinfold, TriS = Triceps Skinfold, SS = Suprailiac Skinfold, 
TS = Thigh Skinfold, %BF = Percent Body Fat 
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Participant 1 Notes 
*Notes were collected via bi-weekly phone call during off weeks from measurement 
collections 
07/05/2018: 
- Has been taking melatonin an hour before bed on a nightly basis 
- Experienced minor dizziness on the first morning, but not debilitating 
- Exercise and diet has remained the same, has changed exercise location due to 
closure of their previous venue 
07/19/2018: 
- Still taking melatonin daily, but has pushed back the time they have been taking 
it, due to later sleep time 
- Feeling great without any side effects 
- No further changes to diet or exercise 
08/01/2018: 
- Has been taking melatonin an hour before bed on a nightly basis 
- Not experiencing any adverse effects 
- Did not work out the previous week due to weather as well as fitness facility 
closure 
- Has been going to bed at a later time 
08/15/2018: 
- Has been taking melatonin an hour before bed on a nightly basis 
- Not experiencing any adverse effects 
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- Continuing usually work out routine, but has missed out on pickle ball due to 
weather 
Additional Notes: 
- Took 53 out of the 56 melatonin pills over the eight week intervention period 
- Claimed to have not felt difference in sleep quality when taking melatonin 
School started when we initiated the second baseline period, and the participant took on 
heavier workload and slowed down on working out during the two-week period
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Participant 2 Notes 
*Notes were collected via bi-weekly phone call during off weeks from measurement 
collections 
07/05/2018: 
- Has been taking melatonin an hour before bed on a nightly basis, and reports that 
it has improved sleep 
o Falling asleep faster 
- Experienced more dreams then usual 
- Ate a little more due to the holiday 
07/19/2018: 
- Still taking melatonin daily, but has pushed back the time they have been taking 
it, due to later sleep time 
- Not experiencing side effects 
- No further changes to diet or exercise 
08/01/2018: 
- Has been taking melatonin an hour before bed around 10-10:30 pm 
- No longer immediately puts them to sleep, but does put them back to sleep after 
waking up around 5-6:00 am 
o Not their usual habit 
- No changes to diet or exercise 
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08/15/2018: 
- Still taking melatonin, but has missed a few days over the course of the 
intervention 
- Not experiencing any adverse effects 
- Was on vacation in the prior week and did not exercise as much as usual 
Additional Notes: 
- Took 53 out of the 56 melatonin pills over the eight week intervention period 
- Melatonin helped participant fall asleep and stay asleep throughout the night 
Once taken off melatonin for baseline, participants could immediately tell the difference 
in their sleep quality
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Participant 3 Notes 
*Notes were collected via bi-weekly phone call during off weeks from measurement 
collections 
07/19/2018: 
- Has been taking melatonin an hour before bed on a nightly basis 
- Not experiencing an side effects 
- Has started to run more 
08/01/2018: 
- Still taking melatonin daily before bed 
- Has been waking up feeling warm, but is not concerned with side effect 
- Has been traveling this past week 
o Sleeping less 
o Still maintaining same amount of exercise (running) 
08/15/2018: 
- Has been taking melatonin an hour before bed on a nightly basis 
- Still waking up feeling warm at night 
o Safety Advisor was informed and approved continued participation 
- Was on vacation for the week, but still maintained exercise habits 
08/29/2018: 
- Has missed one night over the past week, but still staying up to the protocol 
- Not experiencing any adverse effects 
- Has worked out less this week then usual 
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Additional Notes: 
- Took 55 out of the 56 melatonin pills over the eight week intervention period 
- Quality of sleep seemed to decrease during course of intervention, because 
participant kept waking up feeling warm at night 
- When taken off melatonin, participant has been waking up in the morning with 
extreme hunger 
o They think it may be related to lack melatonin or stress 
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Additional Figures
 
Figure 43. Participant 1 Types of 
Activity Performed Per Week 
No trend was seen across amount of time 
spent performing vigorous activity, 
moderate activity, or walking throughout 
the study. 
 
Figure 45. Participant 3 Types of 
Activity Performed Per Week 
No trend was seen across amount of time 
spent performing vigorous activity, 
moderate activity, or walking throughout 
the study.  
 
 
Figure 44. Participant 2 Types of 
Activity Performed Per Week 
No trend was seen across amount of time 
spent performing vigorous activity, 
moderate activity, or walking throughout 
the study. 
  
